• If you are wondering whether Thermo Fisher Scientific at around US$482 per share looks like an opportunity or a stock to be cautious with, the key is understanding what you are actually paying for today.
• The stock has been mixed recently, with the share price down 1.1% over the last week, up 3.3% over the last month and up 21.4% over the last year. The return year to date is down 18.6%, and the three and five year returns are down 5.6% and up 5.1% respectively.
• Investors have been reacting to a steady flow of updates about Thermo Fisher Scientific's role as a major supplier of equipment and services across pharmaceuticals, biotech and diagnostics. These developments can influence expectations about long term demand for its products. Sector wide themes, such as capital spending by drug developers and healthcare providers, have also helped frame how the market looks at the stock's risk and opportunity profile.
• Simply Wall St currently gives Thermo Fisher Scientific a valuation score of 5 out of 6, based on six different undervaluation checks. It is therefore worth looking at what those methods say about the stock and then circling back to an even more complete way to think about valuation at the end of the article.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a company could generate in the future and discounts those cash flows back to what they might be worth in today's dollars. It is essentially asking what a stream of future cash flows is worth right now.

For Thermo Fisher Scientific, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $6.79b. Analysts provide detailed forecasts for the next few years, and Simply Wall St then extends those forecasts further out using its own assumptions. Under this framework, projected Free Cash Flow reaches $11.45b in 2030, with interim years such as 2026 and 2027 estimated at $7.14b and $8.93b respectively before discounting.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $597.73 per share. Compared with a current share price of roughly $482, this set of inputs implies that Thermo Fisher Scientific trades at around a 19.4% discount on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 19.4%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For a profitable company, the P/E ratio is a useful shortcut because it links what you pay for each share to the earnings that the business is currently generating. It gives you a quick way to compare how the stock is being valued against other profitable companies.

What counts as a “normal” P/E depends on how investors view the company’s growth prospects and risks. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth expectations or higher perceived risk tend to justify a lower P/E.

Thermo Fisher Scientific currently trades on a P/E of about 26.16x. That sits below the Life Sciences industry average of 34.25x and below the peer group average of 42.08x. Simply Wall St also calculates a proprietary “Fair Ratio” for Thermo Fisher Scientific of 25.53x, which reflects factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts the expected P/E to the company’s own characteristics rather than treating all companies as identical.

Compared with this Fair Ratio of 25.53x, the current P/E of 26.16x suggests the stock is slightly overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Thermo Fisher Scientific, such as whether tools demand, AI labs and bioprocessing will support a higher fair value closer to about US$738.42, or whether margin pressure and tools headwinds justify something nearer US$520, and link that story to explicit assumptions for future revenue, earnings, margins and P/E. On Simply Wall St's Community page you can compare the Fair Value from your chosen Narrative with the current share price, see whether your story points to the stock being above or below your estimate, and have that view update automatically as new news or earnings arrive.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.